organization · Reporting owner
ARYA Sciences Holdings III
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nautilus Biotechnology, Inc.ARYA · Entity 6679 | 10% owner | August 11, 2020 | August 12, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nautilus Biotechnology, Inc.
Report date August 11, 2020 · Filed August 12, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A ordinary sharesSEC Table I · non-derivative | Direct | 499,000 |
Reported balance
After 2020-08-11 transaction · row 1
1 source rowRow 1 · 2020-08-11 · Other · Acquired 499,000 · Balance 499,000 F1: The reported Class A ordinary shares were purchased as Private Placement Shares by ARYA Sciences Holdings III (the "Sponsor") for $10.00 per share, as described under the heading "Description of Securities " in the Issuer's registration statement on Form S-1 (File No. 333- 239986). |
Filing footnotes · ownership attribution and instrument terms
F1: The reported Class A ordinary shares were purchased as Private Placement Shares by ARYA Sciences Holdings III (the "Sponsor") for $10.00 per share, as described under the heading "Description of Securities " in the Issuer's registration statement on Form S-1 (File No. 333- 239986).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 11, 2020 Filed Aug 12, 2020 00:48 UTC | Nautilus Biotechnology, Inc. ARYA · Entity 6679 | OtherClass A ordinary shares | 499,000 | $10.00 | $4,990,000.00 |
DisclosureSEC source: 0001140361-20-018164 · form4.xml · nonDerivative · entry 1 ARYA Sciences Holdings III · CIK 0001808802 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 499,000 F1 · kind: The reported Class A ordinary shares were purchased as Private Placement Shares by ARYA Sciences Holdings III (the "Sponsor") for $10.00 per share, as described under the heading "Description of Securities " in the Issuer's registration statement on Form S-1 (File No. 333- 239986). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.